Eusol obtained the distribution right of an analgesic medicine from MedRoad/Dae Hwa Pharmaceutical Co., Ltd., South Korea, and is expected to start sales in 2025.
The first drug license for Dae Hwa Ibuprofen was granted to Eusol by TFDA/MOHW in May, 2025.